Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.780
-0.060 (-1.24%)
At close: May 13, 2026, 4:00 PM EDT
4.765
-0.015 (-0.31%)
After-hours: May 13, 2026, 7:22 PM EDT
Nuvation Bio Stock Forecast
Stock Price Forecast
The 8 analysts that cover Nuvation Bio stock have a consensus rating of "Strong Buy" and an average price target of $12.25, which forecasts a 156.28% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $20.
Price Target: $12.25 (+156.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +318.41% | May 5, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +130.13% | May 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +255.65% | May 5, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +130.13% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +130.13% | Apr 2, 2026 |
Financial Forecast
Revenue This Year
194.01M
from 62.90M
Increased by 208.43%
Revenue Next Year
299.08M
from 194.01M
Increased by 54.16%
EPS This Year
-0.48
from -0.60
EPS Next Year
-0.27
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 233.6M | 411.2M | ||||||
| Avg | 194.0M | 299.1M | ||||||
| Low | 139.9M | 214.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 271.4% | 112.0% | ||||||
| Avg | 208.4% | 54.2% | ||||||
| Low | 122.4% | 10.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.34 | - | ||||||
| Avg | -0.48 | -0.27 | ||||||
| Low | -0.90 | -0.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.